A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
304
20mg/tablet
placebo tablet
20mg/tablet
Peking University First hospiatl
Beijing, China
Decrease of sitting diastolic blood pressure at week 16
Time frame: 16 weeks
Decrease of sitting diastolic blood pressure at week 8
Time frame: 8 weeks
Decrease of sitting systolic blood pressure at week 8
Time frame: 8 weeks
Decrease of sitting diastolic blood pressure at week 2
Time frame: 2 weeks
Decrease of sitting diastolic blood pressure at week 4
Time frame: 4 weeks
Decrease of sitting diastolic blood pressure at week 12
Time frame: 12weeks
Decrease of sitting systolic blood pressure at week 2
Time frame: 2 weeks
Decrease of sitting systolic blood pressure at week 4
Time frame: 4 weeks
Decrease of sitting systolic blood pressure at week 12
Time frame: 12 weeks
decrease of 24-hour ambulatory blood pressure monitoring at week 16
do a 24-hour ambulatory blood pressure monitoring at baseline and at week 16, compare the decrease.
Time frame: 16 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
placebo tablet